Why does cancer immunotherapy work differently from patient to patient? Scientists have now found a molecular answer, linking ...

Chimeric antigen receptor (CAR)-modified NK (CAR-NK) cells are candidates for next-generation cancer immunotherapies. Here we generated CD19-specific CAR-NK cells with 4-1BB and CD3ζ signaling ...

NK cells are innate lymphoid cells that can acquire a memory-like phenotype in vitro when stimulated with IL-12, IL-15, and IL-18. These cytokine-induced memory-like (CIML) NK cells exhibit prolonged ...

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...

For NK cell expansion, engineered ARH-77 cells may end the current bottleneck by increasing yield by more than 100,000-fold in one month.

A unique and reliable approach for inducing NK cells from iPSCs (iNK) in a completely feeder-free environment was designed in this study. After 35 days, the cell proportion of CD3-CD56 + iNK Cells ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Natural Killer (NK) cells are vital immune defenders that target and destroy cancer cells. However, in aging and cancer patients, NK cells often become "senescent"—losing their effectiveness due to ...

Natural killer (NK) cells are the bodyguards of our immune system. As a first line of defense, they destroy invading pathogens, foreign bodies, and infected cells in early stages, thereby preventing ...

Immune-evading CAR-NK cells maintained a population in mice long enough to eliminate cancer whilst avoiding cytokine release syndrome. Massachusetts Institute of Technology (MIT) and Harvard Medical ...

ANKL is a rare and aggressive type of blood cancer affecting a type of white blood cell called natural killer (NK) cells. In ANKL, the NK cells are abnormal and multiply out of control, crowding out ...

SENTI-202, a CAR NK cell therapy, achieved complete remission in several relapsed/refractory AML patients, showing potential as an effective treatment option. The off-the-shelf nature of SENTI-202 ...